Paul Klenerman

List of Publications by Year in Descending Order

487 papers	37,734 citations	94 h-index	179 g-index
571 ext. papers	47,701 ext. citations	11.6 avg, IF	7.02 L-index

#	Paper	IF	Citations
487	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. *Cell*, **2022**,	56.2	154
486	Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells.. *Gut*, **2022**,	19.2	2
485	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.. *Cell*, **2022**, 185, 916-938.e58	56.2	17
484	Implementation and Extended Evaluation of the Euroimmun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdom's COVID-19 Public Health Response.. *Microbiology Spectrum*, **2022**, 10, e0228921	8.9	
483	SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients.. *Journal of the American Society of Nephrology: JASN*, **2022**,	12.7	0
482	CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination.. *JCI Insight*, **2022**,	9.9	4
481	Divergent trajectories of antiviral memory after SARS-CoV-2 infection.. *Nature Communications*, **2022**, 13, 1251	17.4	1
480	Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank.. *Nature Communications*, **2022**, 13, 1818	17.4	1
479	A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells.. *Journal of Immunological Methods*, **2022**, 504, 113263	2.5	
478	SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study.. *Journal of Clinical Immunology*, **2022**, 1	5.7	3
477	BreakAlign: a Perl program to align chimaeric (split) genomic NGS reads and allow visual confirmation of novel retroviral integrations.. *BMC Bioinformatics*, **2022**, 23, 134	3.6	1
476	Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study.. *Scientific Reports*, **2022**, 12, 6843	4.9	0
475	The P5-type ATPase ATP13A1 modulates major histocompatibility complex I-related protein 1 (MR1)-mediated antigen presentation.. *Journal of Biological Chemistry*, **2021**, 101542	5.4	0
474	Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. **2021**,		25
473	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. *BMC Infectious Diseases*, **2021**, 21, 1170	4	11
472	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. *Lancet Microbe, The*, **2021**,	22.2	29
471	An immunodominant NP-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. *Nature Immunology*, **2021**,	19.1	19

470	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell*, **2021**, 184, 5699-5714.e11	56.2	64
469	Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. *Nature Communications*, **2021**, 12, 6105	17.4	3
468	Genetic mechanisms of critical illness in COVID-19. *Nature*, **2021**, 591, 92-98	50.4	451
467	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet, The*, **2021**, 396, 1979-1993	40	646
466	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. *Nature Communications*, **2021**, 12, 1951	17.4	25
465	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. *Science Immunology*, **2021**, 6,	28	82
464	Identification and Phenotype of MAIT Cells in Cattle and Their Response to Bacterial Infections. *Frontiers in Immunology*, **2021**, 12, 627173	8.4	4
463	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. *Lancet Respiratory Medicine,the*, **2021**, 9, 699-711	35.1	54
462	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. *Nature Communications*, **2021**, 12, 2055	17.4	37
461	The antigenic anatomy of SARS-CoV-2 receptor binding domain. *Cell*, **2021**, 184, 2183-2200.e22	56.2	145
460	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell*, **2021**, 184, 2348-2361.e6	56.2	549
459	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. *Lancet Respiratory Medicine,the*, **2021**, 9, 349-359	35.1	70
458	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. *Cell*, **2021**, 184, 2201-2211.e7	56.2	269
457	The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D Production Are Attenuated by PGD Receptor 2 Antagonism. *Journal of Immunology*, **2021**, 206, 2714-2724	5.3	1
456	Antibody evasion by the P.1 strain of SARS-CoV-2. *Cell*, **2021**, 184, 2939-2954.e9	56.2	281
455	Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. *BMC Health Services Research*, **2021**, 21, 566	2.9	4
454	Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19. *Allergy, Asthma and Clinical Immunology*, **2021**, 17, 67	3.2	2
453	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. *Lancet Respiratory Medicine,the*, **2021**, 9, 773-785	35.1	35

452	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. *Lancet, The*, **2021**, 398, 223-237	40	39
451	Classification of intestinal T-cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status. *Journal of Pathology*, **2021**, 253, 279-291	9.4	4
450	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. *Nature Medicine*, **2021**, 27, 279-288	50.5	135
449	Human intestinal tissue-resident memory T cells comprise transcriptionally and functionally distinct subsets. *Cell Reports*, **2021**, 34, 108661	10.6	13
448	Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. *EClinicalMedicine*, **2021**, 31, 100683	11.3	164
447	MAIT cell activation augments adenovirus vector vaccine immunogenicity. *Science*, **2021**, 371, 521-526	33.3	27
446	Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic. *Gut*, **2021**, 70, 2398-2400	19.2	5
445	Biological functions of MAIT cells in tissues. *Molecular Immunology*, **2021**, 130, 154-158	4.3	3
444	Real-time seroprevalence and exposure levels of emerging pathogens in infection-naive host populations. *Scientific Reports*, **2021**, 11, 5825	4.9	0
443	Adenovirus vector vaccination reprograms pulmonary fibroblastic niches to support protective inflating memory CD8 T cells. *Nature Immunology*, **2021**, 22, 1042-1051	19.1	9
442	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. *Lancet Rheumatology, The*, **2021**, 3, e498-e506	14.2	30
441	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. *Lancet HIV,the*, **2021**, 8, e474-e485	7.8	62
440	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell*, **2021**, 184, 4220-4236.e13	36.2	256
439	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. *Nature Communications*, **2021**, 12, 5061	17.4	42
438	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. *Lancet Microbe, The*, **2021**, 2, e354-e365	22.2	61
437	Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era. *Frontiers in Medicine*, **2021**, 8, 706482	4.9	8
436	Vaccine efficacy and iron deficiency: an intertwined pair?. *Lancet Haematology,the*, **2021**, 8, e666-e669	14.6	7
435	A Pilot Study on Automatic Three-Dimensional Quantification of Barrett's Esophagus for Risk Stratification and Therapy Monitoring. *Gastroenterology*, **2021**, 161, 865-878.e8	13.3	3

434	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. *PLoS Pathogens*, **2021**, 17, e1009804	7.6	7
433	A prenylated dsRNA sensor protects against severe COVID-19. *Science*, **2021**, 374, eabj3624	33.3	26
432	Interferon-Gamma-Producing CD8 Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis. *Gastroenterology*, **2021**, 161, 1229-1244.e9	13.3	7
431	Expansion of CD161 expressing CD8+ single-positive and CD4+CD8+ double-positive PR3-specific T-cells in granulomatosis with polyangiitis. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 129, 182-183	2.2	
430	Expansion of CD161 expressing CD8+ single-positive and CD4+CD8+ double-positive PR3-specific T-cells in granulomatosis with polyangiitis. *Clinical and Experimental Rheumatology*, **2021**, 39, 182-183	2.2	
429	Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.. *Gut*, **2021**,	19.2	0
428	Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. *Nature Communications*, **2020**, 11, 6385	17.4	62
427	Adenoviral vaccines promote protective tissue-resident memory T cell populations against cancer **2020**, 8,		5
426	Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. *British Journal of Cancer*, **2020**, 123, 207-215	8.7	16
425	MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans. *Science Translational Medicine*, **2020**, 12,	17.5	7
424	Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis. *Journal of Crohnis and Colitis*, **2020**, 14, 1446-1461	1.5	8
423	Characterizing Hepatitis C Virus-Specific CD4 T Cells Following Viral-Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure. *Hepatology*, **2020**, 72, 1541-1555	11.2	10
422	Peripheral CD8 T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. *Nature Medicine*, **2020**, 26, 193-199	50.5	94
421	MAIT Cells in Health and Disease. *Annual Review of Immunology*, **2020**, 38, 203-228	34.7	62
420	Changes in the V7.2+ CD161++ MAIT cell compartment in early pregnancy are associated with preterm birth in HIV-positive women. *American Journal of Reproductive Immunology*, **2020**, 83, e13240	3.8	4
419	The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV. *Vaccines*, **2020**, 8,	5.3	11
418	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. *Wellcome Open Research*, **2020**, 5, 139	4.8	120
417	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. *Wellcome Open Research*, **2020**, 5, 181	4.8	38

416	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. *Wellcome Open Research*, **2020**, 5, 181	4.8	60
415	SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. *Eurosurveillance*, **2020**, 25,	19.8	9
414	Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. *Eurosurveillance*, **2020**, 25,	19.8	36
413	Autophagy in T cells from aged donors is maintained by spermidine and correlates with function and vaccine responses. *ELife*, **2020**, 9,	8.9	17
412	Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients **2020**,		47
411	Transfusion-transmitted hepatitis C: A cluster of cases in transfusion-dependent thalassaemia patients in Sri Lanka. *Transfusion Medicine*, **2020**, 30, 377-383	1.3	1
410	Discordance of hepatitis B vaccination policies for healthcare workers between the USA, the UK, and Germany. *Hepatology Research*, **2020**, 50, 272-282	5.1	2
409	Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. *Value in Health*, **2020**, 23, 180-190	3.3	0
408	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 1656-1665	10.2	72
407	Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV. *Reviews in Medical Virology*, **2020**, 30, e2144	11.7	44
406	Single-cell oxygen saturation imaging shows that gas exchange by red blood cells is not impaired in COVID-19 patients. *British Journal of Haematology*, **2020**, 190, e229-e232	4.5	6
405	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet, The*, **2020**, 396, 467-478	40	1274
404	MAIT Cells in Barrier Tissues: Lessons from Immediate Neighbors. *Frontiers in Immunology*, **2020**, 11, 584824	7.1	8
403	Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans. *Npj Vaccines*, **2020**, 5, 94	9.5	5
402	Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nature Immunology*, **2020**, 21, 1336-1345	19.1	615
401	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *Lancet Infectious Diseases, The*, **2020**, 20, 1390-1400	25.5	212
400	Hypoxic gene expression in chronic hepatitis B virus infected patients is not observed in state-of-the-art in vitro and mouse infection models. *Scientific Reports*, **2020**, 10, 14101	4.9	8
399	A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals. *Nature Immunology*, **2020**, 21, 1232-1243	19.1	23

398	Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus. *Hepatology*, **2020**, 71, 794-807	11.2	11
397	First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults. *Clinical Infectious Diseases*, **2020**, 70, 2073-2081	11.6	25
396	Human MAIT Cell Activation In Vitro. *Methods in Molecular Biology*, **2020**, 2098, 97-124	1.4	7
395	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). *European Journal of Immunology*, **2019**, 49, 1457-1973	6.1	485
394	Association Between Impaired V□7.2+CD161++CD8+ (MAIT) and V□7.2+CD161-CD8+ T-Cell Populations and Gut Dysbiosis in Chronically HIV- and/or HCV-Infected Patients. *Frontiers in Microbiology*, **2019**, 10, 1972	5.7	14
393	Maintenance of Functional CD57+ Cytolytic CD4+ T Cells in HIV+ Elite Controllers. *Frontiers in Immunology*, **2019**, 10, 1844	8.4	13
392	Activation and In□Vivo Evolution of the MAIT Cell Transcriptome in Mice and Humans Reveals Tissue Repair Functionality. *Cell Reports*, **2019**, 28, 3249-3262.e5	10.6	79
391	TCR and Inflammatory Signals Tune Human MAIT Cells to Exert Specific Tissue Repair and Effector Functions. *Cell Reports*, **2019**, 28, 3077-3091.e5	10.6	91
390	Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells. *Journal of Allergy and Clinical Immunology*, **2019**, 144, 1722-1726.e10	11.5	1
389	Antibody opsonization enhances MAIT cell responsiveness to bacteria via a TNF-dependent mechanism. *Immunology and Cell Biology*, **2019**, 97, 538-551	5	13
388	CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype. *Mucosal Immunology*, **2019**, 12, 1212-1219	9.2	16
387	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. *Value in Health*, **2019**, 22, 693-703	3.3	8
386	Nrf2 controls iron homeostasis in haemochromatosis and thalassaemia via Bmp6 and hepcidin. *Nature Metabolism*, **2019**, 1, 519-531	14.6	46
385	Diabetes alters immune response patterns to acute melioidosis in humans. *European Journal of Immunology*, **2019**, 49, 1092-1106	6.1	24
384	Successful direct-acting antiviral therapy in HIV/HCV co-infected patients fails to restore circulating mucosal-associated invariant T cells. *European Journal of Immunology*, **2019**, 49, 1127-1129	6.1	8
383	The hallmarks of CMV-specific CD8 T-cell differentiation. *Medical Microbiology and Immunology*, **2019**, 208, 365-373	4	34
382	Immunotherapy-related hepatitis: real-world experience from a tertiary centre. *Frontline Gastroenterology*, **2019**, 10, 364-371	2.6	31
381	HBV vaccination and PMTCT as elimination tools in the presence of HIV: insights from a clinical cohort and dynamic model. *BMC Medicine*, **2019**, 17, 43	11.4	11

380	Inflation vs. Exhaustion of Antiviral CD8+ T-Cell Populations in Persistent Infections: Two Sides of the Same Coin?. *Frontiers in Immunology*, **2019**, 10, 197	8.4	10
379	Conservation of the OmpC Porin Among Typhoidal and Non-Typhoidal Serovars. *Frontiers in Immunology*, **2019**, 10, 2966	8.4	2
378	Divergent memory responses driven by adenoviral vectors are impacted by epitope competition. *European Journal of Immunology*, **2019**, 49, 1356-1363	6.1	0
377	Single-cell transcriptome analysis of CD8 T-cell memory inflation. *Wellcome Open Research*, **2019**, 4, 78	4.8	5
376	Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. *ELife*, **2019**, 8,	8.9	17
375	Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults. *Journal of Infection*, **2019**, 78, 382-392	18.9	24
374	Perturbation of mucosal-associated invariant T cells and iNKT cells in HIV infection. *Current Opinion in HIV and AIDS*, **2019**, 14, 77-84	4.2	12
373	Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis. *Clinical and Translational Gastroenterology*, **2019**, 10, e00020	4.2	16
372	Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. *PLoS ONE*, **2019**, 14, e0210407	3.7	10
371	Antiviral activity of bone morphogenetic proteins and activins. *Nature Microbiology*, **2019**, 4, 339-351	26.6	19
370	Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis. *Hepatology Communications*, **2018**, 2, 421-436	6	21
369	The (gradual) rise of memory inflation. *Immunological Reviews*, **2018**, 283, 99-112	11.3	46
368	Induction and Maintenance of CX3CR1-Intermediate Peripheral Memory CD8 T Cells by Persistent Viruses and Vaccines. *Cell Reports*, **2018**, 23, 768-782	10.6	40
367	Human MAIT cells show metabolic quiescence with rapid glucose-dependent upregulation of granzyme B upon stimulation. *Immunology and Cell Biology*, **2018**, 96, 666-674	5	19
366	MAIT cells and viruses. *Immunology and Cell Biology*, **2018**, 96, 630-641	5	59
365	Oxford Screening CSF and Respiratory samples (ROSCARP): results of a pilot study to screen clinical samples from a diagnostic microbiology laboratory for viruses using Illumina next generation sequencing. *BMC Research Notes*, **2018**, 11, 120	2.3	5
364	Innate-like CD8+ T-cells and NK cells: converging functions and phenotypes. *Immunology*, **2018**, 154, 547	7.8	21
363	Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C. *Hepatology*, **2018**, 68, 859-871	11.2	15

362	Prolonged Evolution of Virus-Specific Memory T Cell Immunity after Severe Avian Influenza A (H7N9) Virus Infection. *Journal of Virology*, **2018**, 92,	6.6	16
361	Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and Pathogen. *Frontiers in Immunology*, **2018**, 9, 1561	8.4	22
360	Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections. *Frontiers in Immunology*, **2018**, 9, 276	8.4	56
359	CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells. *Frontiers in Immunology*, **2018**, 9, 486	8.4	49
358	Unique and Common Features of Innate-Like Human V□ □ Cells and Mucosal-Associated Invariant T Cells. *Frontiers in Immunology*, **2018**, 9, 756	8.4	30
357	Impact of Interferon-□Receptor-1 Promoter Polymorphisms on the Transcriptome of the Hepatitis B Virus-Associated Hepatocellular Carcinoma. *Frontiers in Immunology*, **2018**, 9, 777	8.4	6
356	CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA. *Frontiers in Immunology*, **2018**, 9, 928	8.4	26
355	Insights Into Mucosal-Associated Invariant T Cell Biology From Studies of Invariant Natural Killer T Cells. *Frontiers in Immunology*, **2018**, 9, 1478	8.4	38
354	Evidence of CD4 T cell-mediated immune pressure on the Hepatitis C virus genome. *Scientific Reports*, **2018**, 8, 7224	4.9	13
353	Killer T cells show their kinder side. *Nature*, **2018**, 555, 594-595	50.4	4
352	Synergistic activation of pro-inflammatory type-2 CD8 T lymphocytes by lipid mediators in severe eosinophilic asthma. *Mucosal Immunology*, **2018**, 11, 1408-1419	9.2	35
351	Consequences of Identifying XIAP Deficiency in an Adult Patient With Inflammatory Bowel Disease. *Gastroenterology*, **2018**, 155, 231-234	13.3	12
350	The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes. *Vaccine*, **2018**, 36, 313-321	4.1	24
349	Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease. *Gut*, **2018**, 67, 918-930	19.2	71
348	MAIT cells contribute to protection against lethal influenza infection in vivo. *Nature Communications*, **2018**, 9, 4706	17.4	103
347	Memory inflation following adenoviral vaccination depends on IL-21. *Vaccine*, **2018**, 36, 7011-7016	4.1	2
346	Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort. *BMC Infectious Diseases*, **2018**, 18, 461	4	13
345	Nanopore sequencing and full genome de novo assembly of human cytomegalovirus TB40/E reveals clonal diversity and structural variations. *BMC Genomics*, **2018**, 19, 577	4.5	14

344	Diverse Streptococcus pneumoniae Strains Drive a Mucosal-Associated Invariant T-Cell Response Through Major Histocompatibility Complex class I-Related Molecule-Dependent and Cytokine-Driven Pathways. *Journal of Infectious Diseases*, **2018**, 217, 988-999	7	37
343	Cysteinyl leukotriene E activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D and epithelial cytokines. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 1090-1100.e11	11.5	100
342	Significance of anti-HBc alone serological status in clinical practice. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 123-134	18.8	28
341	Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. *Nature Genetics*, **2017**, 49, 666-673	36.3	81
340	No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort. *Pancreatology*, **2017**, 17, 395-402	3.8	16
339	Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101. *Hepatology*, **2017**, 66, 57-68	11.2	25
338	Short Communication: Lack of Effect of Maraviroc Intensification on Blood and Gut Reservoir. *AIDS Research and Human Retroviruses*, **2017**, 33, 143-146	1.6	5
337	Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency. *Immunity*, **2017**, 46, 148-161	32.3	273
336	The Human Cell Atlas **2017**,		41
335	Cytomegalovirus (CMV) Epitope-Specific CD4 T Cells Are Inflated in HIV CMV Subjects. *Journal of Immunology*, **2017**, 199, 3187-3201	5.3	24
334	Targeted reconstruction of T cell receptor sequence from single cell RNA-seq links CDR3 length to T cell differentiation state. *Nucleic Acids Research*, **2017**, 45, e148	20.1	61
333	Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities. *PLoS ONE*, **2017**, 12, e0184496	3.7	2
332	Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. *Antiviral Research*, **2017**, 146, 139-145	10.8	10
331	Immunology taught by rats. *Science*, **2017**, 357, 129-130	33.3	4
330	Cytometric Gating Stringency Impacts Studies of Type 2 Innate Lymphoid Cells in Asthma. *American Journal of Respiratory Cell and Molecular Biology*, **2017**, 57, 745-747	5.7	4
329	The Role of CD4+ T Follicular Helper Cells in HIV Infection: From the Germinal Center to the Periphery. *Frontiers in Immunology*, **2017**, 8, 46	8.4	19
328	Shared and Distinct Phenotypes and Functions of Human CD161++ V□7.2+ T Cell Subsets. *Frontiers in Immunology*, **2017**, 8, 1031	8.4	71
327	The Human Cell Atlas. *ELife*, **2017**, 6,	8.9	937

326	Human parvovirus 4 (PARV4) remains elusive despite a decade of study. *F1000Research*, **2017**, 6, 82	3.6	11
325	PARV4 prevalence, phylogeny, immunology and coinfection with HIV, HBV and HCV in a multicentre African cohort. *Wellcome Open Research*, **2017**, 2, 26	4.8	9
324	Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005263	4.8	30
323	Adenoviral vaccine induction of CD8+ T cell memory inflation: Impact of co-infection and infection order. *PLoS Pathogens*, **2017**, 13, e1006782	7.6	7
322	Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus. *Hepatology*, **2016**, 64, 1934-1950	11.2	28
321	MAIT cells are activated during human viral infections. *Nature Communications*, **2016**, 7, 11653	17.4	283
320	Human T cell responses to Japanese encephalitis virus in health and disease. *Journal of Experimental Medicine*, **2016**, 213, 1331-52	16.6	63
319	Human endogenous retrovirus (HERV) expression is not induced by treatment with the histone deacetylase (HDAC) inhibitors in cellular models of HIV-1 latency. *Retrovirology*, **2016**, 13, 10	3.6	14
318	The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. *Gut*, **2016**, 65, 112-23	19.2	24
317	HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults. *Journal of Infectious Diseases*, **2016**, 213, 1248-52	7	7
316	Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1. *Journal of Hepatology*, **2016**, 64, 1118-1127	13.4	115
315	LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation. *Journal of Immunology*, **2016**, 196, 2085-94	5.3	27
314	Modification of Antigen Impacts on Memory Quality after Adenovirus Vaccination. *Journal of Immunology*, **2016**, 196, 3354-63	5.3	13
313	A new perspective of the structural complexity of HCMV-specific T-cell responses. *Mechanisms of Ageing and Development*, **2016**, 158, 14-22	5.6	20
312	Expression of lectin-like transcript-1 in human tissues. *F1000Research*, **2016**, 5, 2929	3.6	11
311	Impact of IL-27 on hepatocyte antiviral gene expression and function. *Wellcome Open Research*, **2016**, 1, 17	4.8	5
310	Hepitopes: A live interactive database of HLA class I epitopes in hepatitis B virus. *Wellcome Open Research*, **2016**, 1, 9	4.8	18
309	A Rapid-Response Humoral Vaccine Platform Exploiting Pre-Existing Non-Cognate Populations of Anti-Vaccine or Anti-Viral CD4+ T Helper Cells to Confirm B Cell Activation. *PLoS ONE*, **2016**, 11, e0166383	3.7	8

308	Cytomegalovirus Reinfections Stimulate CD8 T-Memory Inflation. *PLoS ONE*, **2016**, 11, e0167097	3.7	22
307	Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function. *PLoS Pathogens*, **2016**, 12, e1005782	7.6	32
306	Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection. *PLoS Pathogens*, **2016**, 12, e1005894	7.6	25
305	Peptide Processing Is Critical for T-Cell Memory Inflation and May Be Optimized to Improve Immune Protection by CMV-Based Vaccine Vectors. *PLoS Pathogens*, **2016**, 12, e1006072	7.6	44
304	Elevation of CpG frequencies in influenza A genome attenuates pathogenicity but enhances host response to infection. *ELife*, **2016**, 5, e12735	8.9	68
303	Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. *Vaccines*, **2016**, 4,	5.3	27
302	Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR. *Emerging Infectious Diseases*, **2016**, 22, 671-8	10.2	34
301	Genome-wide association of multiple complex traits in outbred mice by ultra-low-coverage sequencing. *Nature Genetics*, **2016**, 48, 912-8	36.3	81
300	Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a. *Hepatology*, **2016**, 64, 1377-8	11.2	4
299	Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes. *Journal of Clinical Microbiology*, **2016**, 54, 2470-84	9.7	78
298	A contaminant-free assessment of Endogenous Retroviral RNA in human plasma. *Scientific Reports*, **2016**, 6, 33598	4.9	9
297	Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. *Hepatology*, **2016**, 63, 1455-70	11.2	32
296	T cell responses to cytomegalovirus. *Nature Reviews Immunology*, **2016**, 16, 367-77	36.5	253
295	MAIT cells: new guardians of the liver. *Clinical and Translational Immunology*, **2016**, 5, e98	6.8	109
294	Multi-functional lectin-like transcript-1: A new player in human immune regulation. *Immunology Letters*, **2016**, 177, 62-9	4.1	16
293	TLR signaling in human antigen-presenting cells regulates MR1-dependent activation of MAIT cells. *European Journal of Immunology*, **2016**, 46, 1600-14	6.1	80
292	Antibody responses to influenza viruses in paediatric patients and their contacts at the onset of the 2009 pandemic in Mexico. *Journal of Infection in Developing Countries*, **2015**, 9, 259-66	2.3	2
291	Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing. *Journal of Clinical Microbiology*, **2015**, 53, 3155-64	9.7	25

290	Methodologies for the Analysis of HCV-Specific CD4(+) T Cells. *Frontiers in Immunology*, **2015**, 6, 57	8.4	8
289	Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. *Gut*, **2015**, 64, 813-9	19.2	53
288	Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. *Science Translational Medicine*, **2015**, 7, 300ra126	17.5	93
287	Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalk. *Journal of Allergy and Clinical Immunology*, **2015**, 135, 1358-66.e1-11	11.5	40
286	Molecular Analyses Define V□7.2-J□33+ MAIT Cell Depletion in HIV Infection: A Case-Control Study. *Medicine (United States)*, **2015**, 94, e1134	1.8	18
285	Increased IgG4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG4-related disease. *Annals of the Rheumatic Diseases*, **2015**, 74, 944-7	2.4	30
284	Effects of neutralizing antibodies on escape from CD8+ T-cell responses in HIV-1 infection. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2015**, 370,	5.8	4
283	Human parvovirus 4 infection among mothers and children in South Africa. *Emerging Infectious Diseases*, **2015**, 21, 713-5	10.2	8
282	Ongoing burden of disease and mortality from HIV/CMV coinfection in Africa in the antiretroviral therapy era. *Frontiers in Microbiology*, **2015**, 6, 1016	5.7	71
281	Prevalence and Characteristics of Hepatitis B Virus (HBV) Coinfection among HIV-Positive Women in South Africa and Botswana. *PLoS ONE*, **2015**, 10, e0134037	3.7	38
280	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. *Clinical Cancer Research*, **2015**, 21, 3347-3355	12.9	184
279	Screening and treatment for hepatitis C: a balanced perspective. *BMJ, The*, **2015**, 350, h644	5.9	1
278	Increasing inflationary T-cell responses following transient depletion of MCMV-specific memory T cells. *European Journal of Immunology*, **2015**, 45, 113-8	6.1	15
277	Differential Immune Profiles in Two Pandemic Influenza A(H1N1)pdm09 Virus Waves at Pandemic Epicenter. *Archives of Medical Research*, **2015**, 46, 651-8	6.6	6
276	An update on hepatitis C virus. *Clinical Medicine*, **2015**, 15 Suppl 6, s33-6	1.9	2
275	Adenoviral Vector Vaccination Induces a Conserved Program of CD8(+) T Cell Memory Differentiation in Mouse and Man. *Cell Reports*, **2015**, 13, 1578-88	10.6	31
274	Hepatitis C. *Lancet, The*, **2015**, 385, 1124-35	40	365
273	Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes. *European Journal of Immunology*, **2015**, 45, 309-16	6.1	27

272	An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes. *Virology*, **2015**, 476, 355-363	3.6	18
271	ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens. *F1000Research*, **2015**, 4, 1062	3.6	39
270	CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. *PLoS Pathogens*, **2015**, 11, e1005177	7.6	183
269	CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. *European Journal of Immunology*, **2014**, 44, 195-203	6.1	340
268	A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis. *Journal of Immunology*, **2014**, 193, 2306-16	5.3	27
267	Phylogeography and epidemic history of hepatitis C virus genotype 4 in Africa. *Virology*, **2014**, 464-465, 233-243	3.6	57
266	Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 1184-94	11.5	343
265	Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. *Journal of Clinical Virology*, **2014**, 61, 20-33	14.5	117
264	CD73 is dispensable for the regulation of inflationary CD8+ T-cells after murine cytomegalovirus infection and adenovirus immunisation. *PLoS ONE*, **2014**, 9, e114323	3.7	4
263	Autophagy is a critical regulator of memory CD8(+) T cell formation. *ELife*, **2014**, 3,	8.9	199
262	CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. *Cell Reports*, **2014**, 9, 1075-88	10.6	181
261	A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. *Science Translational Medicine*, **2014**, 6, 261ra153	17.5	233
260	Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. *PLoS Pathogens*, **2014**, 10, e1004210	7.6	161
259	PARV4: an emerging tetraparvovirus. *PLoS Pathogens*, **2014**, 10, e1004036	7.6	21
258	Hepatitis E virus infection, Papua New Guinea, Fiji, and Kiribati, 2003-2005. *Emerging Infectious Diseases*, **2014**, 20, 1057-8	10.2	13
257	Programmed death-1 expression on HIV-1-specific CD8+ T cells is shaped by epitope specificity, T-cell receptor clonotype usage and antigen load. *Aids*, **2014**, 28, 2007-21	3.5	9
256	Gamma Delta T-lymphocytes in Hepatitis C and Chronic Liver Disease. *Frontiers in Immunology*, **2014**, 5, 400	8.4	37
255	Mucosal-associated invariant T-cells: new players in anti-bacterial immunity. *Frontiers in Immunology*, **2014**, 5, 450	8.4	109

254	Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV. *Cell Host and Microbe*, **2014**, 15, 471-83	23.4	49
253	Ever closer to a prophylactic vaccine for HCV. *Expert Opinion on Biological Therapy*, **2013**, 13, 1109-24	5.4	44
252	FavourablePIL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. *Journal of General Virology*, **2013**, 94, 1259-1265	4.9	18
251	Mutant prolactin receptor and familial hyperprolactinemia. *New England Journal of Medicine*, **2013**, 369, 2012-2020	59.2	80
250	Hepatitis C virus infections in the Democratic Republic of Congo exhibit a cohort effect. *Infection, Genetics and Evolution*, **2013**, 19, 386-94	4.5	31
249	CD8Expression Marks Terminally Differentiated Human CD8+ T Cells Expanded in Chronic Viral Infection. *Frontiers in Immunology*, **2013**, 4, 223	8.4	14
248	Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines. *Human Vaccines and Immunotherapeutics*, **2013**, 9, 1741-51	4.4	5
247	Age-associated increase of low-avidity cytomegalovirus-specific CD8+ T cells that re-express CD45RA. *Journal of Immunology*, **2013**, 190, 5363-72	5.3	57
246	Evolution of CD8+ T cell responses after acute PARV4 infection. *Journal of Virology*, **2013**, 87, 3087-96	6.6	13
245	Eight novel hepatitis C virus genomes reveal the changing taxonomic structure of genotype 6. *Journal of General Virology*, **2013**, 94, 76-80	4.9	16
244	Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection. *Blood*, **2013**, 121, 951-61	2.2	237
243	A new model for CD8+ T cell memory inflation based upon a recombinant adenoviral vector. *Journal of Immunology*, **2013**, 190, 4162-74	5.3	34
242	A modified RNA-Seq approach for whole genome sequencing of RNA viruses from faecal and blood samples. *PLoS ONE*, **2013**, 8, e66129	3.7	52
241	Low levels of peripheral CD161++CD8+ mucosal associated invariant T (MAIT) cells are found in HIV and HIV/TB co-infection. *PLoS ONE*, **2013**, 8, e83474	3.7	76
240	Infection frequency of hepatitis C virus and IL28B haplotypes in Papua New Guinea, Fiji, and Kiribati. *PLoS ONE*, **2013**, 8, e66749	3.7	7
239	Human MAIT and CD8cells develop from a pool of type-17 precommitted CD8+ T cells. *Blood*, **2012**, 119, 422-33	2.2	202
238	Transient CD8-memory contraction: a potential contributor to latent cytomegalovirus reactivation. *Journal of Leukocyte Biology*, **2012**, 92, 933-7	6.5	11
237	The impact of differential antiviral immunity in children and adults. *Nature Reviews Immunology*, **2012**, 12, 636-48	36.5	128

236	CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. *Journal of Hepatology*, **2012**, 57, 1044-51	13.4	136
235	Memory T cell inflation: understanding cause and effect. *Trends in Immunology*, **2012**, 33, 84-90	14.4	103
234	T cell responses in hepatitis C: the good, the bad and the unconventional. *Gut*, **2012**, 61, 1226-34	19.2	113
233	Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. *PLoS ONE*, **2012**, 7, e39603	3.7	34
232	Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. *Science Translational Medicine*, **2012**, 4, 115ra1	17.5	310
231	HCV genotype-3a T cell immunity: specificity, function and impact of therapy. *Gut*, **2012**, 61, 1589-99	19.2	15
230	Rapid antigen processing and presentation of a protective and immunodominant HLA-B*27-restricted hepatitis C virus-specific CD8+ T-cell epitope. *PLoS Pathogens*, **2012**, 8, e1003042	7.6	21
229	A new evolutionary model for hepatitis C virus chronic infection. *PLoS Pathogens*, **2012**, 8, e1002656	7.6	30
228	Parvovirus 4 infection and clinical outcome in high-risk populations. *Journal of Infectious Diseases*, **2012**, 205, 1816-20	7	28
227	Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. *Science Translational Medicine*, **2012**, 4, 115ra2	17.5	210
226	Rituximab in Cryoglobulinemic Vasculitis: First- or Second-Line Therapy? **2012**, 307-313		1
225	MIGRAs: are they the new IGRAs? Development of monokine-amplified IFN-release assays. *Biomarkers in Medicine*, **2012**, 6, 177-86	2.3	8
224	A novel method for autophagy detection in primary cells: impaired levels of macroautophagy in immunosenescent T cells. *Autophagy*, **2012**, 8, 677-89	10.2	115
223	Leukotriene E4 activates human Th2 cells for exaggerated proinflammatory cytokine production in response to prostaglandin D2. *Journal of Immunology*, **2012**, 188, 694-702	5.3	29
222	Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 14562-7	11.5	32
221	CD161(+)CD4(+) T cells are enriched in the liver during chronic hepatitis and associated with co-secretion of IL-22 and IFN- *Frontiers in Immunology*, **2012**, 3, 346	8.4	25
220	Prospective monitoring reveals dynamic levels of T cell immunity to Mycobacterium tuberculosis in HIV infected individuals. *PLoS ONE*, **2012**, 7, e37920	3.7	6
219	Inflammation in common variable immunodeficiency is associated with a distinct CD8(+) response to cytomegalovirus. *Journal of Allergy and Clinical Immunology*, **2011**, 127, 1385-93.e4	11.5	24

218	Vaccination for hepatitis C virus: closing in on an evasive target. *Expert Review of Vaccines*, **2011**, 10, 659-72	5.2	86
217	The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. *Journal of General Virology*, **2011**, 92, 2227-2236	4.9	20
216	Impact of host responses on control of hepatitis C virus infection in Chinese blood donors. *Biochemical and Biophysical Research Communications*, **2011**, 415, 503-8	3.4	4
215	CD161-expressing human T cells. *Frontiers in Immunology*, **2011**, 2, 36	8.4	66
214	A molecular assay for sensitive detection of pathogen-specific T-cells. *PLoS ONE*, **2011**, 6, e20606	3.7	25
213	Effect of immune pressure on hepatitis C virus evolution: insights from a single-source outbreak. *Hepatology*, **2011**, 53, 396-405	11.2	49
212	Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. *Hepatology*, **2011**, 53, 1446-54	11.2	53
211	New approaches for biomarker discovery: the search for liver fibrosis markers in hepatitis C patients. *Journal of Proteome Research*, **2011**, 10, 2643-50	5.6	17
210	Interferon lambdas: the next cytokine storm. *Gut*, **2011**, 60, 1284-93	19.2	89
209	High frequency, sustained T cell responses to PARV4 suggest viral persistence in vivo. *Journal of Infectious Diseases*, **2011**, 203, 1378-87	7	23
208	Differential B7-CD28 costimulatory requirements for stable and inflationary mouse cytomegalovirus-specific memory CD8 T cell populations. *Journal of Immunology*, **2011**, 186, 3874-81	5.3	40
207	Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection. *Gut*, **2011**, 60, 1563-71	19.2	64
206	Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. *Gut*, **2011**, 60, 837-45	19.2	131
205	A dominant role for the immunoproteasome in CD8+ T cell responses to murine cytomegalovirus. *PLoS ONE*, **2011**, 6, e14646	3.7	68
204	Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. *PLoS ONE*, **2011**, 6, e16797	3.7	19
203	Progression to AIDS in South Africa is associated with both reverting and compensatory viral mutations. *PLoS ONE*, **2011**, 6, e19018	3.7	50
202	Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. *Journal of Clinical Investigation*, **2011**, 121, 1223-1223	15.9	78
201	Commercially available outbred mice for genome-wide association studies. *PLoS Genetics*, **2010**, 6, e1001085	8.1	102

200	Hepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution. *Journal of Virology*, **2010**, 84, 1656-63	6.6	66
199	Dynamic coinfection with multiple viral subtypes in acute hepatitis C. *Journal of Infectious Diseases*, **2010**, 202, 1770-9	7	28
198	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. *Gut*, **2010**, 59, 1252-8	19.2	39
197	Full-Length Characterization of Hepatitis C Virus Subtype 3a Reveals Novel Hypervariable Regions under Positive Selection during Acute Infection. *Journal of Virology*, **2010**, 84, 1664-1664	6.6	78
196	MHC-peptide tetramers for the analysis of antigen-specific T cells. *Expert Review of Vaccines*, **2010**, 9, 765-74	5.2	45
195	Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 3006-11	11.5	269
194	A genetic and functional relationship between T cells and cellular proliferation in the adult hippocampus. *PLoS Biology*, **2010**, 8, e1000561	9.7	27
193	Virus-specific CD4+ T cell responses in chronic HCV infection in blood and liver identified by antigen-specific upregulation of CD154. *Journal of Hepatology*, **2010**, 52, 800-11	13.4	16
192	B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. *Nature Communications*, **2010**, 1, 102	17.4	55
191	HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. *Aids*, **2010**, 24, 491-502	3.5	127
190	Antiviral prevention of sepsis induced cytomegalovirus reactivation in immunocompetent mice. *Antiviral Research*, **2010**, 85, 496-503	10.8	24
189	Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro. *Hepatology*, **2010**, 52, 443-53	11.2	79
188	The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, **2010**, 104, 475-83	2	32
187	Cellular immunity in children with successful immunoprophylactic treatment for mother-to-child transmission of hepatitis B virus. *BMC Infectious Diseases*, **2010**, 10, 103	4	17
186	Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection. *Journal of General Virology*, **2010**, 91, 1396-406	4.9	25
185	Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa. *Antiviral Therapy*, **2009**, 14, 975-84	1.6	21
184	What are the prospects for controlling hepatitis C?. *PLoS Medicine*, **2009**, 6, e1000096	11.6	6
183	High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. *Journal of Infectious Diseases*, **2009**, 200, 1119-25	7	61

182	HLA footprints on human immunodeficiency virus type 1 are associated with interclade polymorphisms and intraclade phylogenetic clustering. *Journal of Virology*, **2009**, 83, 4605-15	6.6	35
181	Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection. *Journal of Virology*, **2009**, 83, 11456-66	6.6	23
180	Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. *Journal of Infectious Diseases*, **2009**, 199, 819-28	7	39
179	Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. *Hepatology*, **2009**, 49, 1069-82	11.2	115
178	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. *Hepatology*, **2009**, 50, 1017-29	11.2	50
177	The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. *Immunology*, **2009**, 128, 83-91	7.8	57
176	Adaptation of HIV-1 to human leukocyte antigen class I. *Nature*, **2009**, 458, 641-5	50.4	361
175	Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. *Nature Immunology*, **2009**, 10, 636-46	19.1	153
174	Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. *Gastroenterology*, **2009**, 137, 1289-300	13.3	279
173	Genetic history of hepatitis C virus in East Asia. *Journal of Virology*, **2009**, 83, 1071-82	6.6	169
172	Development of novel treatments for hepatitis C. *Lancet Infectious Diseases, The*, **2009**, 9, 108-17	25.5	60
171	Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. *Journal of Clinical Investigation*, **2009**, 119, 376-86	15.9	84
170	Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis. *Clinical Immunology*, **2008**, 127, 144-50	9	57
169	Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. *Journal of Clinical Virology*, **2008**, 41, 92-5	14.5	28
168	CMV and the art of memory maintenance. *Immunity*, **2008**, 29, 520-2	32.3	16
167	Hepatitis C vaccine: supply and demand. *Lancet Infectious Diseases, The*, **2008**, 8, 379-86	25.5	61
166	Escape from HLA-B*08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs. *Journal of Virology*, **2008**, 82, 11803-12	6.6	42
165	High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. *Journal of Virology*, **2008**, 82, 3154-60	6.6	159

164	Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. *Journal of Virology*, **2008**, 82, 3438-51	6.6	53
163	Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus. *Journal of Infectious Diseases*, **2008**, 198, 813-7	7	26
162	Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. *Journal of Infectious Diseases*, **2008**, 197, 990-9	7	104
161	CD161 expression on hepatitis C virus-specific CD8+ T cells suggests a distinct pathway of T cell differentiation. *Hepatology*, **2008**, 47, 396-406	11.2	66
160	Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. *Journal of Clinical Investigation*, **2008**, 118, 1143-53	15.9	33
159	Immune Responses Against the Hepatitis C Virus and the Outcome of Therapy **2008**, 71-86		
158	Dynamics of killer T cell inflation in viral infections. *Journal of the Royal Society Interface*, **2007**, 4, 533-43	4.1	16
157	Protection of hepatocytes from cytotoxic T cell mediated killing by interferon-alpha. *PLoS ONE*, **2007**, 2, e791	3.7	20
156	Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population. *Journal of Medical Virology*, **2007**, 79, 724-33	19.7	45
155	Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point. *Journal of Virology*, **2007**, 81, 5759-65	6.6	65
154	Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. *Journal of Virology*, **2007**, 81, 434-8	6.6	83
153	Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. *Journal of Immunology*, **2007**, 178, 5217-26	5.3	226
152	HCV-HIV coinfection: simple messages from a complex disease. *PLoS Medicine*, **2007**, 4, e240	11.6	23
151	AIDS/HIV. Finding footprints among the trees. *Science*, **2007**, 315, 1505-7	33.3	9
150	Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. *Journal of Hepatology*, **2007**, 47, 316-24	13.4	129
149	Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. *PLoS ONE*, **2007**, 2, e649	3.7	58
148	CD4+ T cell responses in hepatitis C virus infection. *World Journal of Gastroenterology*, **2007**, 13, 4831-8	5.6	40
147	HIV-specific CD8 T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memory. *Virology*, **2006**, 353, 366-73	3.6	42

146	Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. *Hepatology*, **2006**, 43, 563-72	11.2	169
145	Aberrant cellular immune responses in humans infected persistently with parvovirus B19. *Journal of Medical Virology*, **2006**, 78, 129-33	19.7	24
144	Bone marrow transplantation from a pediatric donor with a high frequency of cytomegalovirus-specific T-cells. *Journal of Medical Virology*, **2006**, 78, 1616-23	19.7	6
143	Tracking of peptide-specific CD4+ T-cell responses after an acute resolving viral infection: a study of parvovirus B19. *Journal of Virology*, **2006**, 80, 11209-17	6.6	21
142	Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. *Journal of Immunology*, **2006**, 177, 450-8	5.3	188
141	Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy. *Blood*, **2006**, 107, 4570-1	2.2	30
140	Cytotoxic T lymphocytes and viral adaptation in HIV infection. *Current Opinion in HIV and AIDS*, **2006** , 1, 241-8	4.2	3
139	Large scale analysis of pediatric antiviral CD8+ T cell populations reveals sustained, functional and mature responses. *Immunity and Ageing*, **2006**, 3, 11	9.7	30
138	Genome-wide genetic association of complex traits in heterogeneous stock mice. *Nature Genetics*, **2006**, 38, 879-87	36.3	442
137	PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. *Nature*, **2006**, 443, 350-4	50.4	2001
136	A protocol for high-throughput phenotyping, suitable for quantitative trait analysis in mice. *Mammalian Genome*, **2006**, 17, 129-46	3.2	88
135	Longitudinal analysis of CD8 T-cell responses to HIV and hepatitis C virus in a cohort of co-infected haemophiliacs. *Aids*, **2005**, 19, 1135-43	3.5	8
134	T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. *Lancet, The*, **2005**, 365, 327-9	40	42
133	HCV-indeterminate blood donors or occult HCV infection?. *Lancet, The*, **2005**, 365, 1541	40	
132	The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. *Blood*, **2005**, 105, 1170-8	2.2	96
131	Liver cell lines for the study of hepatocyte functions and immunological response. *Liver International*, **2005**, 25, 389-402	7.9	49
130	Does memory improve with age? CD85j (ILT-2/LIR-1) expression on CD8 T cells correlates with ‘memory inflation’ in human cytomegalovirus infection. *Immunology and Cell Biology*, **2005**, 83, 182-8	5	59
129	T cells and viral persistence: lessons from diverse infections. *Nature Immunology*, **2005**, 6, 873-9	19.1	328

128	Evolution of diverse antiviral CD8+ T cell populations after murine cytomegalovirus infection. *European Journal of Immunology*, **2005**, 35, 1113-23	6.1	132
127	Properties of murine (CD8+)CD27- T cells. *European Journal of Immunology*, **2005**, 35, 3131-41	6.1	56
126	Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. *Hepatology*, **2005**, 41, 1019-28	11.2	145
125	Prolonged activation of virus-specific CD8+T cells after acute B19 infection. *PLoS Medicine*, **2005**, 2, e343	11.6	74
124	Unique acquisition of cytotoxic T-lymphocyte escape mutants in infant human immunodeficiency virus type 1 infection. *Journal of Virology*, **2005**, 79, 12100-5	6.6	35
123	Ex vivo characterization of early secretory antigenic target 6-specific T cells at sites of active disease in pleural tuberculosis. *Clinical Infectious Diseases*, **2005**, 40, 184-7	11.6	140
122	Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. *Journal of Virology*, **2005**, 79, 12365-74	6.6	143
121	Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. *Journal of Experimental Medicine*, **2005**, 201, 891-902	16.6	198
120	Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. *Journal of Virology*, **2005**, 79, 12117-21	6.6	35
119	A theoretical framework for quantitative analysis of the molecular basis of costimulation. *Journal of Immunology*, **2005**, 175, 1575-85	5.3	42
118	Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. *Journal of Immunology*, **2005**, 175, 6334-43	5.3	82
117	Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. *Journal of Virology*, **2005**, 79, 12979-88	6.6	93
116	Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. *Journal of Virology*, **2005**, 79, 7852-9	6.6	235
115	HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. *Journal of Immunology*, **2005**, 174, 7524-30	5.3	99
114	HIV-1□specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. *Journal of Clinical Investigation*, **2005**, 115, 443-450	15.9	43
113	HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. *Journal of Clinical Investigation*, **2005**, 115, 443-50	15.9	26
112	Underwhelming the immune response: effect of slow virus growth on CD8+-T-lymphocyte responses. *Journal of Virology*, **2004**, 78, 2247-54	6.6	81
111	Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. *Journal of Immunology*, **2004**, 172, 1744-53	5.3	85

110	Analysis of 'driver' and 'passenger' CD8+ T-cell responses against variable viruses. *Proceedings of the Royal Society B: Biological Sciences*, **2004**, 271 Suppl 3, S53-6	4.4	16
109	Underwhelming the Immune Response: Effect of Slow Virus Growth on CD8 + -T-Lymphocyte Responses. *Journal of Virology*, **2004**, 78, 6079-6079	6.6	78
108	Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. *Journal of Virology*, **2004**, 78, 2255-64	6.6	92
107	CD8 epitope escape and reversion in acute HCV infection. *Journal of Experimental Medicine*, **2004**, 200, 1593-604	16.6	263
106	High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. *Journal of Virology*, **2004**, 78, 3447-54	6.6	71
105	Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 3382-9	5.9	50
104	Ex vivo phenotype and frequency of influenza virus-specific CD4 memory T cells. *Journal of Virology* , **2004**, 78, 7284-7	6.6	63
103	Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. *Nature*, **2004**, 432, 769-75	50.4	681
102	Virus-specific CD8+ T lymphocytes within the normal human liver. *European Journal of Immunology*, **2004**, 34, 1526-31	6.1	29
101	Commentary: T cells get by with a little help from their friends. *European Journal of Immunology*, **2004**, 34, 313-6	6.1	9
100	Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells. *European Journal of Immunology*, **2004**, 34, 1570-7	6.1	52
99	Cellular immune responses against HCV: T cells take a diversion in the liver. *Hepatology*, **2004**, 40, 1459-1461	11.2	
98	High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. *Gastroenterology*, **2004**, 127, 924-36	13.3	257
97	Immunology of hepatitis C virus **2004**, 107-123		
96	Suppression of Hepatitis C Virus Replication is Maintained Long Term following Haart Therapy, in An Individual with HCV/HIV Co-Infection. *Antiviral Therapy*, **2004**, 9, 139-142	1.6	9
95	Alterations in the phenotype of CMV-specific and total CD8+ T-cell populations in Wegener's granulomatosis. *Cellular Immunology*, **2003**, 224, 1-7	4.4	11
94	Modelling the dynamics of LCMV infection in mice: II. Compartmental structure and immunopathology. *Journal of Theoretical Biology*, **2003**, 221, 349-78	2.3	16
93	Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. *Hepatology*, **2003**, 38, 1468-76	11.2	89

92	Viral escape and T cell exhaustion in hepatitis C virus infection analysed using Class I peptide tetramers. *Immunology Letters*, **2003**, 85, 165-71	4.1	45
91	The influence of macrophage inflammatory protein-1alpha on protective immunity mediated by antiviral cytotoxic T cells. *Immunology*, **2003**, 109, 68-75	7.8	22
90	Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 1855-60	11.5	51
89	Frequency and phenotype of circulating Valpha24/Vbeta11 double-positive natural killer T cells during hepatitis C virus infection. *Journal of Virology*, **2003**, 77, 2251-7	6.6	91
88	Viral coinfections among African children infected with human immunodeficiency virus type 1. *Clinical Infectious Diseases*, **2003**, 36, 922-4	11.6	36
87	Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. *Journal of Immunology*, **2003**, 170, 2022-9	5.3	339
86	Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. *Journal of Clinical Investigation*, **2003**, 112, 831-42	15.9	128
85	Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. *Journal of Clinical Investigation*, **2003**, 112, 831-842	15.9	210
84	Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4+ T cells. *European Journal of Immunology*, **2002**, 32, 374-82	6.1	38
83	Optimization of peptide linker length in production of MHC class II/peptide tetrameric complexes increases yield and stability, and allows identification of antigen-specific CD4+T cells in peripheral blood mononuclear cells. *European Journal of Immunology*, **2002**, 32, 3366-75	6.1	22
82	Immunity to hepatitis C virus: stunned but not defeated. *Microbes and Infection*, **2002**, 4, 57-65	9.3	29
81	Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. *Nature Medicine*, **2002**, 8, 379-85	50.5	1302
80	Tracking T cells with tetramers: new tales from new tools. *Nature Reviews Immunology*, **2002**, 2, 263-72	36.5	150
79	Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. *Journal of Virology*, **2002**, 76, 6104-13	6.6	175
78	The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. *Hepatology*, **2002**, 36, 743-54	11.2	112
77	T cell failure in hepatitis C virus infection. *Viral Immunology*, **2002**, 15, 285-93	1.7	18
76	HIV/AIDS. HLA leaves its footprints on HIV. *Science*, **2002**, 296, 1410-1	33.3	59
75	Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. *Journal of Virology*, **2002**, 76, 2817-26	6.6	94

74	Effects of promyelocytic leukemia protein on virus-host balance. *Journal of Virology*, **2002**, 76, 3810-8	6.6	91
73	HIV: current opinion in escapology. *Current Opinion in Microbiology*, **2002**, 5, 408-13	7.9	78
72	T lymphocyte responses against human parvovirus B19: small virus, big response. *Pathologie Et Biologie*, **2002**, 50, 317-25		8
71	Viral escape mechanisms--escapology taught by viruses. *International Journal of Experimental Pathology*, **2001**, 82, 269-86	2.8	62
70	Studies of human antiviral CD8+ lymphocytes using class I peptide tetramers. *Reviews in Medical Virology*, **2001**, 11, 11-22	11.7	37
69	Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. *European Journal of Immunology*, **2001**, 31, 2388-94	6.1	108
68	A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. *Journal of Immunological Methods*, **2001**, 249, 99-110	2.5	138
67	CD8+ cytotoxic lymphocyte responses against cytomegalovirus after liver transplantation: correlation with time from transplant to receipt of tacrolimus. *Journal of Infectious Diseases*, **2001**, 183, 835-43	7	31
66	Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. *Journal of Immunology*, **2001**, 167, 5217-25	5.3	294
65	Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. *Journal of Virology*, **2001**, 75, 5550-8	6.6	425
64	Low level viral persistence after infection with LCMV: a quantitative insight through numerical bifurcation analysis. *Mathematical Biosciences*, **2001**, 173, 1-23	3.9	28
63	Impairment of CD4(+) T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. *Journal of Experimental Medicine*, **2001**, 193, 297-305	16.6	82
62	Direct quantitation of rapid elimination of viral antigen-positive lymphocytes by antiviral CD8(+) T cells in vivo. *European Journal of Immunology*, **2000**, 30, 1356-63	6.1	69
61	CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. *European Journal of Immunology*, **2000**, 30, 2479-87	6.1	283
60	Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. *Immunological Reviews* , **2000**, 174, 77-89	11.3	77
59	Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence. *Journal of Virology*, **2000**, 74, 5896-901	6.6	25
58	Characterization of a novel respiratory syncytial virus-specific human cytotoxic T-lymphocyte epitope. *Journal of Virology*, **2000**, 74, 7694-7	6.6	43
57	Analysis of successful immune responses in persons infected with hepatitis C virus. *Journal of Experimental Medicine*, **2000**, 191, 1499-512	16.6	1081

56	Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2000**, 355, 1085-92	5.8	27
55	Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. *Journal of Biological Chemistry*, **1999**, 274, 34089-95	5.4	189
54	Cytotoxic T lymphocytes, chemokines and antiviral immunity. *Trends in Immunology*, **1999**, 20, 212-6		63
53	General and specific immunosuppression caused by antiviral T-cell responses. *Immunological Reviews*, **1999**, 168, 305-15	11.3	45
52	CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. *Journal of Virology*, **1999**, 73, 4120-6	6.6	98
51	The impact of variation in the number of CD8(+) T-cell precursors on the outcome of virus infection. *Cellular Immunology*, **1998**, 189, 67-73	4.4	44
50	Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. *Nature*, **1998**, 394, 482-5	50.4	278
49	The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection. *Journal of Molecular Medicine*, **1998**, 76, 699-708	5.5	32
48	Dynamics of cytotoxic T-lymphocyte exhaustion. *Proceedings of the Royal Society B: Biological Sciences*, **1998**, 265, 191-203	4.4	63
47	What can we learn about human immunodeficiency virus infection from a study of lymphocytic choriomeningitis virus?. *Immunological Reviews*, **1997**, 159, 5-16	11.3	37
46	A non-retroviral RNA virus persists in DNA form. *Nature*, **1997**, 390, 298-301	50.4	142
45	Immune surveillance and AIDS progression. *Current Biology*, **1997**, 7, R403-5	6.3	
44	A functional and kinetic comparison of antiviral effector and memory cytotoxic T lymphocyte populations in vivo and in vitro. *European Journal of Immunology*, **1997**, 27, 3404-13	6.1	80
43	Antagonist HIV-1 Gag peptides induce structural changes in HLA B8. *Journal of Experimental Medicine*, **1996**, 184, 2279-86	16.6	123
42	Cytotoxic T-cell antagonism in HIV-1. *Seminars in Virology*, **1996**, 7, 31-39		11
41	Immune escape through T cell antagonism? **1996**, 361-368		
40	Antigenic oscillations and shifting immunodominance in HIV-1 infections. *Nature*, **1995**, 375, 606-11	50.4	293
39	The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. *European Journal of Immunology*, **1995**, 25, 1927-31	6.1	68

38	Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. *Nature*, **1994**, 369, 403-7	50.4	387
37	Mosquitoes: how to be the perfect host. *International Journal of Dermatology*, **1989**, 28, 370-2	1.7	3
36	TCR and inflammatory signals tune human MAIT cells to exert specific tissue repair and effector functions		4
35	Activation and in vivo evolution of the MAIT cell transcriptome in mice and humans reveals diverse functionality		7
34	Activation of MAIT cells plays a critical role in viral vector vaccine immunogenicity		2
33	Targeted reconstruction of T cell receptor sequence from single cell RNA-sequencing links CDR3 length to T cell differentiation state		5
32	Enrichment of the HIV reservoir in CD32+ CD4 T cells occurs early in blood and tissue		2
31	Fundamental principles of epidemic spread highlight the immediate need for large-scale serological surveys to assess the stage of the SARS-CoV-2 epidemic		109
30	Detection of neutralising antibodies to SARS coronavirus 2 to determine population exposure in Scottish blood donors between March and May 2020		33
29	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel		55
28	Negative regulation of ACE2 by interferons in vivo and its genetic control		3
27	SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus		10
26	Genetic mechanisms of critical illness in Covid-19		51
25	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses		7
24	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2		6
23	Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge		4
22	Maintenance therapy with infliximab or vedolizumab in inflammatory bowel disease is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic		2
21	Human Herpes Virus 6 (HHV-6) - Pathogen or Passenger? A pilot study of clinical laboratory data and next generation sequencing		3

20	MAIT cells contribute to protection against lethal influenza infection in vivo		3
19	Human intestinal tissue-resident memory CD8+ T cells comprise transcriptionally and functionally distinct subsets		2
18	DiverseStreptococcus pneumoniaestrains drive a MAIT cell response through MR1-dependent and cytokine-driven pathways		1
17	HBV vaccination and PMTCT as elimination tools in the presence of HIV: insights from a clinical cohort and dynamic model		2
16	Immune Responses to Persistent Viruses255-267		
15	Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2		14
14	In vivo negative regulation of SARS-CoV-2 receptor, ACE2, by interferons and its genetic control. *Wellcome Open Research*,6, 47	4.8	0
13	Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era		1
12	Two doses of SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 variants of concern than does natural infection.		7
11	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses		6
10	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity		4
9	Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune pathways related to tissue injury		1
8	Divergent trajectories of antiviral memory after SARS-Cov-2 infection		4
7	Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection. *SSRN Electronic Journal*,	1	3
6	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. *SSRN Electronic Journal*,	1	2
5	Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern.		27
4	Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity The OCTAVE Trial. *SSRN Electronic Journal*,	1	19
3	T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. *SSRN Electronic Journal*,	1	13

2	Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum		3
1	MAIT cells in liver inflammation and fibrosis. *Seminars in Immunopathology*,	12	0